The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | Novel CLL therapy highlights from ASH 2017
Data for non-chemotherapy-based treatments is increasing exponentially, with the presentations at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, proving no exception to this trend. In this interview, Anthony Mato, MD, MSCE, of the University of Pennsylvania, Philadelphia, PA, discusses the most promising therapeutic areas in chronic lymphocytic leukemia (CLL) from the meeting. He expresses excitement at the long-term follow-up data for ibrutinib and acalabrutinib, as well as expanding roles for 2nd generation kinase inhibitors and combinations utilizing venetoclax.
